The signal

AstraZeneca's announcement in late April was the clearest marker. Having paused a £200 million expansion at its Cambridge site in 2025, the company confirmed it is restarting that project and adding a further £100 million at Macclesfield, £300 million in total, attributed directly to the new pharmaceutical arrangement struck between the UK and the US earlier this year. The Prime Minister called the commitment "highly symbolic." It is also, more practically, a signal that the UK's largest pharmaceutical employers are once again treating domestic manufacturing as a place to put serious capital.

AstraZeneca isn't alone. In the same window:

Sterling Pharma Solutions confirmed a second-phase expansion at its Deeside site, investing over £10 million to more than double its antibody-drug conjugate manufacturing capacity, a response to what the company describes as a "recognised global shortage of capacity for scale-up" in ADC development. The new suite includes a 1,400 sq ft Grade C cleanroom built to handle highly potent molecules at occupational exposure band 5, among the most demanding containment standards in pharmaceutical manufacturing.

Intertek expanded its GMP pharmaceutical stability storage facility near Cambridge to 625,000 litres of capacity, consolidating its position as one of the largest contract storage sites in Europe, a direct response to the volume of new drug development programmes now moving through UK facilities.

And the Life Sciences Innovative Manufacturing Fund continues to do the work it was designed for. UCB has committed £500 million to a new R&D and manufacturing biologics hub in Surrey. Accord is investing £45 million at its Barnstaple site. Norgine is spending £20 million expanding its Welsh manufacturing operation. The University of Birmingham's Precision Health Technologies Accelerator is building three GMP cleanrooms specifically because, as its CEO put it, the West Midlands "urgently needs GMP cleanroom facilities" despite hosting over half the UK's clinical trials for advanced therapies.

What this means for enterprise manufacturers planning their own facilities

Each of these projects is different in scale and purpose. What they share is instructive. None of them are speculative. Every one is being built against a specific, named capacity gap, ADC manufacturing, stability storage, near-patient biomanufacturing, biologics production, identified by a company or institution that already understands exactly what it needs and why.

That specificity matters more than it might first appear. The enterprise pharmaceutical facilities being committed to right now are not generic GMP space. They are precise responses to named bottlenecks: the global shortage of ADC scale-up capacity Sterling is solving for, the near-patient manufacturing gap PHTA is closing, the biologics hub UCB has decided the UK market justifies. A facility built to solve a defined capacity problem performs differently from one built to a generic specification and adapted afterwards.

This is where the brief matters as much as the budget. An enterprise pharmaceutical facility, fill-finish, biologics, ADC, advanced therapy manufacturing, carries regulatory, containment and validation requirements that have to be designed in from the first conversation, not layered on once the architecture is fixed. Occupational exposure banding for highly potent compounds, water-for-injection systems, and environmental monitoring and qualification protocols all shape the building at a structural level. Retrofitting any of these into a facility designed without them in mind is materially more expensive, and materially slower, than designing for them from day one.

Why integrated delivery matters most at enterprise scale

At enterprise scale, the cost of getting the brief wrong compounds. A delay in cleanroom validation pushes back a regulatory submission. A containment specification that's revised mid-build adds months, not weeks. A facility procured through separate architecture, engineering and construction contracts, each handing off to the next, multiplies the points where a misunderstanding between disciplines becomes a costly correction once the building is already underway.

Our approach is to bring architecture, engineering and construction into the same conversation from the outset, with one team accountable for the whole facility rather than three contracts each accountable for a fragment of it. On a recent cGMP fill-finish project, that integrated model meant the facility was delivered ahead of schedule and on budget, directly because the MEP engineering and the regulatory requirements were understood and designed for before a single wall went up, not discovered once the build was already in motion.

We have been delivering GMP and pharmaceutical manufacturing facilities in the UK for over 60 years, working across cleanroom classification from ISO 5 to ISO 8, fill-finish environments, biomanufacturing suites and advanced therapy production. If your organisation is among those planning the next phase of UK manufacturing investment, the conversation that matters most is the one that happens before the brief is finalised.

What this means if you're planning a facility now

The current wave of investment, AstraZeneca, Sterling, Intertek, UCB, Accord, Norgine, PHTA, confirms that UK enterprise pharmaceutical manufacturing is genuinely back in growth mode, not just recovering from a pause. For any organisation with a facility decision in front of it, that's both an opportunity and a reason for urgency: the specialist contractors, MEP engineers and validation consultants capable of delivering this kind of facility well are the same pool of expertise every other enterprise manufacturer in this wave is also competing for.

The facilities that get delivered on time and on budget are, almost without exception, the ones where that conversation started early.

Talk to our pharmaceuticals team →

Sources

1. AstraZeneca UK manufacturing investment, £300m, April 2026 — Manufacturing Digital

2. Sterling Pharma Solutions, Deeside ADC capacity expansion — Sterling Pharma Solutions

3. Intertek GMP stability storage expansion, Royston — Intertek

4. UCB, Accord, Norgine and PHTA manufacturing investments via LSIMF — VWV

5. University of Birmingham, PHTA near-patient biomanufacturing facility — University of Birmingham

Inuti is a global design and engineering firm delivering advanced facilities for science, with over 60 years of experience and 712,000+ sq ft delivered. We work with life sciences, pharmaceutical, agri-tech and technology companies at every stage of growth, across the UK and beyond.

inuti.com · Get in touch